This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

HighVista Strategies sold 69,092 shares of Structure Therapeutics (GPCR 2.89%) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing. What happened According to an SEC filing dated May 15, 2026, HighVista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the…

Read More

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics (DNTH +0.96%), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Cormorant Asset Management added a new position in Dianthus Therapeutics…

Read More